AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.
Also called NCT03317002
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 129 participants
- Sponsor
- Registry
-
NCT03317002
-
- Other papers using this trial's data
- Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Denmark, Finland, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT03317002. Randomized; triple masking; primary purpose treatment. Start 2017-10-30 (actual); primary completion 2020-04-08 (actual). Results posted on 2021-06-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).
- Acronym
- FLAVOUR
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- AZD5718
- Intervention (Drug)
- AZD5718
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct03317002- Content hash
d21e14eedf3c7aecbd3379fc6b6b90261180aa557b54fe550b89fa37de6b54a2